Atherothrombosis in South Asians: Implications of atherosclerotic and inflammatory markers

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 45-50

  Dodani, Sunita ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Coronary artery disease; Dysfunctional HDL; South Asians

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

AGE; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ASIAN; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COMMON CAROTID ARTERY; CORONARY ARTERY DISEASE; DISEASE MARKER; DYSLIPIDEMIA; ECHOGRAPHY; ETHNICITY; HEART INFARCTION; HUMAN; IMMIGRANT; INFLAMMATION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SOUTH ASIAN;

EID: 78249271740     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010045     Document Type: Article

References (67)

1. Uppaluri CR. Heart disease and its related risk factors in Asian Indians. Ethn Dis 2002; 12: 45-53.
2. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007; 297: 286-294.
3. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immi-grant Asian Indians to the United States of America. Indian Heart J 1996; 48: 343-353.
4. Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and treatment. Clin Cardiol 1995; 18: 131-135.
5. Enas EA, Yusuf S, Mehta J. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol 1992; 70: 945-949.
6. Mohan V, Deepa R, Rani SS, Premalatha G. Chennai Urban Popu-lation Study (CUPS No.5). Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001; 38: 688-9.
7. McKeigue PM, Marmot MG. Mortality from coronary heart disease in Asian communities in London. BMJ 1988; 297: 903.
8. Cappuccio F, Cook D, Atkinson R, Strazzullo P. Prevalence, detec-tion, and management of cardiovascular risk factors in different ethnic groups in south London. Heart 1997; 78: 555-563.
9. Bhopal R, Hayes L, White M, Unwin N, Harland J, Ayis S. Ethnic and socio-economic inequalities in coronary heart disease, diabetes and risk factors in Europeans and South Asians. J Public Health Med 2002; 24: 95-105.
10. Bhatnagar D, Anand IS, Durrington PN, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995; 345: 405-9.
11. Patel JV, Vyas A, Cruickshank JK, et al. Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis 2006; 185:297-306.
12. Patel S, Unwin N, Bhopal R, et al. A comparison of proxy meas-ures of abdominal obesity in Chinese, European and South Asian adults. Diabet Med 1999; 16: 853-860.
13. Din JN, Ashman OA, Aftab SM, Jubb AW, Newby DE, Flapan AD. Increased arterial stiffness in healthy young South Asian men. J Hum Hypertens 2006; 20: 163-5.
14. Toutouzas P, Richter D. Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the EN-HANCE trial. Angiology 2008; 59 (2 Suppl): 77S-79S.
15. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006; 124: 235-244.
16. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: sub-clinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000; 20: 823-829.
17. Pasternak RC, Abrams J, Greenland P, Smaha LA, Wilson PW, Houston-Miller N. 34th Bethesda Conference: task force #1--Identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003; 41: 1863-1874.
18. Devine PJ, Carlson DW, Taylor AJ. Clinical value of carotid in-tima-media thickness testing. J Nucl Cardiol 2006; 13: 710-8.
19. Patel SN, Rajaram V, Pandya S, Fiedler BM, Bai CJ, Neems R. Emerging, noninvasive surrogate markers of atherosclerosis. Curr Atheroscler Rep 2004; 6: 60-8.
20. Smith SC, Greenland P, Grundy SM. Prevention Conference V. Beyond Secondary Prevention: identifying the high-risk patient for primary prevention. Executive Summary. Circulation 2000; 101: 111-116.
21. Egger M, Krasinski A, Rutt BK, Fenster A, Parraga G. Comparison of B-mode ultrasound, 3-dimensional ultrasound, and magnetic resonance imaging measurements of carotid atherosclerosis. J Ultrasound Med 2008; 27: 1321-1334.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 77: 1399-406.
23. O'Leary DH, Polak JF, Wolfson SK Jr, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1991; 22: 1155-1163.
24. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiography 2008; 21: 93-111.
25. Howard G, Manolio TA, Burke GL, Wolfson SK, O'Leary DH. Does the association of risk factors and atherosclerosis change with age? An analysis of the combined ARIC and CHS cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Stroke 1997; 28: 1693-1701.
26. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and ma-jor risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-494.
27. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima-media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999; 30: 841-850.
28. Bots ML, Breslau PJ, Briet E, et al. Cardiovascular determinants of carotid artery disease: the Rotterdam Elderly Study. Hypertension 1992; 19: 717-720.
29. Hughes K, Yeo PP, Lun KC, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Commun Health 1990; 44: 29-35.
30. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood pressure in adults (ATP III). Third report of the National Cholesterol Education Pro-gram (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (ATP III) final report. Circulation 2002; 106: 3121-3143.
31. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardio-vascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610.
32. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004; 364: 937-952.
33. Ridker PM, Hennekens CH, Buring JE, Cook NR, Rifai N. C-reactive protein and other markers of inflammation in the predic-tion of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
34. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368: 647-658.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregres-sion analysis of published data from 20 studies of 95,783 individu-als followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
36. Jadhav UM, Kadam NN. Carotid intima-media thickness as an independent predictor of coronary artery disease. Indian Heart J 2001; 53: 458-462.
37. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993; 24: 1297-1304.
38. Dodani S, Marion L, Sharma G, Reed GL, George V. The associa-tion of carotid intima media thickness with dysfunctional HDL in South Asians. Arch Med Sci 2008; 4: 40-6.
39. Dodani S, Kaur R, Reddy S, Reed GL, Navab M, George V. Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int J Cardiol 2008; 129: 125-132.
40. Tang R, Hennig M, Bond MG, Hollweck R, Mancia G, Zanchetti A. Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis. J Hypertens 2005; 23: 1047-1054.
41. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on be-half of the advisory board of the 3rd and 4th watching the risk symposium 13th and 15th European stroke conferences, Mann-heim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23: 75-78.
42. Lorenz MW, Markus SH, Bots ML, Rosval M and Sitzer M. Pre-diction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-467.
43. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and ma-jor risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 1997; 146: 483-494.
44. Du Clos TW. Function of C-reactive protein. Ann Med 2000; 32: 274-278.
45. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascu-lar disease. Ann Intern Med 2006; 145: 35-42.
46. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322.
47. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366: 1954-1959.
48. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events. Circu-lation 2003; 108: 2993-2999.
49. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115: 981-989.
50. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardio-vascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855.
51. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145.
52. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive pro-tein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001; 25: 1327.
53. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipo-protein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
54. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol 2003; 23: 712-719.
55. Williams DL, Connelly MA, Temel RE, et al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol 1999; 10: 329-339.
56. Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent path-way. Proc Natl Acad Sci USA 1999; 96: 11358-11363.
57. Remaley AT, Stonik JA, Demosky SJ, et al. Apolipoprotein speci-ficity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun 2001; 280: 818-823.
58. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
59. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2002; 278: 3937-3947.
60. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13: 285-288.
61. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
62. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 2006; 8: 405-411.
63. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005; 46: 1792-1798.
64. Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeop-ardy of HDL. Ann Med 2005; 37: 173-8.
65. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541.
66. Dodani S, Dong Y, Zhu H, George V. Can novel Apo A-I poly-morphisms be responsible for low HDL in South Asian immigrants. Indian J Hum Genet 2008; 14: 9-15.
67. Gasparyan AY. The Use of Carotid Artery Ultrasonography in Different Clinical Conditions. Open Cardiovasc Med J 2009; 3: 78-80.